January 17, 2014
“The Physician’s Perspective: A health policy brief from the Institute for Patient Access,” discusses the importance of a doctor’s need to know when their patients are switched to a biosimilar –- an issue public policy makers in the states are currently considering. Read more here.
January 17, 2014
“The Physician’s Perspective: A health policy brief from the Institute for Patient Access,” discusses the importance of a doctor’s need to know when their patients are switched to a biosimilar –- an issue public policy makers in the states are currently considering. Read more here.
November 22, 2013
Dublin, Ireland – The Alliance for Safe Biologic Medicines (ASBM) today released the results of a new survey on European physicians’ views on biosimilar naming. ASBM Executive Director Michael Reilly presented the findings at the Drug Information Association (DIA) Biosimilars Workshop in Dublin, Ireland. The key findings showed that nonproprietary names matter to patient safety. […]
November 21, 2013
Dr. Dolinar discusses biosimilars with Seth Ginsberg of the Global Healthy Living Foundation on WFAS AM 1230 talk radio, Greater NYC. Listen here.
November 15, 2013
The Alliance for Patient Access (AfPA) held their National Physicians Biologics Working Group Meeting on November 15-16 in Chicago, IL where Dr. Dolinar gave the keynote address to attending physicians. In his address, Dr. Dolinar discussed the current state of biosimilars and explained the disconnect between the science and potential policies and how they will impact […]
November 6, 2013
On October 26, Dr. Richard Dolinar served as the keynote luncheon speaker at the National Association of Latino Elected and Appointed Officials (NALEO) Legislative Summit on Health in Las Vegas. Dr. Dolinar discussed the science and policy issues surrounding biosimilar provisions of the Patient Protection and Affordable Care Act with state legislators from across the […]
October 28, 2013
The Alliance for Safe Biologic Medicines (ASBM) executive director, Michael Reilly, was featured in a Globe & Mail video series on biosimilars. Mr. Reilly provides a global perspective on biosimilars, with a focus on why manufacturing matters. Globe & Mail is the national newspaper for Canada and this new online series will provide viewers with […]
October 28, 2013
The Alliance for Safe Biologic Medicines (ASBM) executive director, Michael Reilly, was featured in a Globe & Mail video series on biosimilars. Mr. Reilly provides a global perspective on biosimilars, with a focus on why manufacturing matters. Globe & Mail is the national newspaper for Canada and this new online series will provide viewers with […]
October 28, 2013
Allow ‘biosimilars’ in Pennsylvania These medications will improve health and cut costs The Pennsylvania Legislature is considering a measure to make sure patients have safe access to an important new class of drugs called “biosimilars.” If the bill passes, Pennsylvania will follow North Dakota, Oregon, Utah and Virginia in taking this critical legislative action. “Biosimilars” […]
October 22, 2013
ASBM Presents at WHO Meeting on Naming in Geneva Calls for Distinct Non-Proprietary Names to Ensure Patient Safety Geneva, Switzerland – The Alliance for Safe Biologic Medicines (ASBM) today presented at the World Health Organization’s (WHO) 57th Consultation on International Nonproprietary Names (INN) for Pharmaceutical Substances in Geneva, Switzerland. During his presentation, ASBM Chairman, Richard […]
